QST, Blink Reflex and Nociceptive Flexion Reflex in Headache

Quantitative Sensory Testing, Blink Reflex and Nociceptive Flexion Reflex in the Pathophysiology of Headache

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04585698

Enrollment

Registered

2020-10-14

Start date

2020-10-31

Completion date

2021-10-31

Last updated

2020-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head Pain

Keywords

headache, fremanezumab, blink reflex, nociceptive flexion reflex, quantitative sensory testing

Brief summary

The aim of this study is to compare central and peripheric sensitization in headache patients at Baseline (T0) and 1 month after (T1) a treatment with an anti-CGRP (Fremanezumab-Ajovy).

Detailed description

20 patients and 20 healthy subjects will be enrolled. The headache patients will be recruited just before starting their treatment and 1 month after (corresponding to the efficacy peak). Hot and cold stimulations will be delivered with the ATS probe from the Medoc Pathway on the forehead and on the hand (palmar face) to determine painful threshold to warm/cold stimuli. A blink reflex will be generated with a concentric electrode placed over the eyebrow and with active/earth electrodes linked to the EMG machine for the recording. For the nociceptive flexion reflex, a cutaneous stimulation will be applied on the arm and the response recorded on the corresponding muscles.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

patients with headache which are about to receive a treatment with fremanezumab

Exclusion criteria

* medication changes 1 month prior to the test * neuropathy * acute or chronic pain * medications having effects on the central nervous system * other disease

Design outcomes

Primary

Measure	Time frame	Description
modulation of pain threshold by fremanezumab	one year	quantitative analysis of pain-related reflexes with QST (quantitative sensory testing) using Medoc Pathway

Outcome results